These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25304031)

  • 1. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.
    Meng D; Chen Y; Yun D; Zhao Y; Wang J; Xu T; Li X; Wang Y; Yuan L; Sun R; Song X; Huai C; Hu L; Yang S; Min T; Chen J; Chen H; Lu D
    Oncotarget; 2015 Mar; 6(7):4901-19. PubMed ID: 25669971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.
    Jarboe JS; Anderson JC; Duarte CW; Mehta T; Nowsheen S; Hicks PH; Whitley AC; Rohrbach TD; McCubrey RO; Chiu S; Burleson TM; Bonner JA; Gillespie GY; Yang ES; Willey CD
    Clin Cancer Res; 2012 Jun; 18(11):3030-41. PubMed ID: 22619307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
    Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
    Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
    Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
    Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.
    Huang QR; Li JW; Pan XB
    Medicine (Baltimore); 2021 Dec; 100(48):e28065. PubMed ID: 35049227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
    Guan Y; He Y; Lv S; Hou X; Li L; Song J
    J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
    Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
    Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and validation of an immune-based prognostic score model in glioblastoma.
    Qin Z; Zhang X; Chen Z; Liu N
    Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
    Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
    World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Proliferation by Knockdown of Transmembrane (TMEM) 168 in Glioblastoma Cells via Suppression of Wnt/β-Catenin Pathway.
    Xu J; Su Z; Ding Q; Shen L; Nie X; Pan X; Yan A; Yan R; Zhou Y; Li L; Lu B
    Oncol Res; 2019 Jul; 27(7):819-826. PubMed ID: 30940290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
    Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
    J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
    Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
    J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme.
    Qian Z; Li Y; Ma J; Xue Y; Xi Y; Hong L; Dai X; Zhang Y; Ji X; Chen Y; Sheng M; Sheng Y; Yang L; Liu J; Dai X; Shi J; Xie T; Dong J
    J Neurooncol; 2018 Nov; 140(2):199-208. PubMed ID: 29995176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
    Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
    Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.